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INTRODUCTION 
 
DEFINITION 
 
 The  American  Thoracic  Society  defines  COPD  as a disorder 
characterized  by  abnormal tests of expiratory flow [ on a structural or 
functional basis ]  tha do not change markedly over several months of 
observation. The  diagnosis  usually  refers to the presence of chronic 
obstructive bronchitis  with varying degrees of emphysema and bronchospasm[ 
asthmatic bronchospasm] .            
 
 The  American Thoracic Society , defines  chronic obstructive 
pulmonary Disease  [ COPD]  as a  disease state characterized by  the presence 
of airwayObstruction  due to chronic bronchitis or emphysema  ; the airflow 
obstruction is 
 
Generally  progressive ,may be accompanied by airway hypersensitivity  
and            
may  be partially reversible   . Diagnostic of this non specific entity are  chronic  
productive cough, breathlessness on exertion, physiological evidence of  
airflow 
 Limitation[ reduced FEV1] ,and poor reversibility[ e.g , response to 
bronchodilator]             
 
EMPHYSEMA 
 
 This entity  is  defined in anatomic terms -- abnormal  
permanentEnlargement of the   gas –exchanging units of the  lungs[acini] in 
associationThe predominant physiologic consequence of  these  anatomic 
abnormalitiess,a decrease  in the  elastic  recoil  of  the lungs – which inturn 
causesOutward  displacement of the  chest wall  and  flattening of  the 
diaphragm. Hyperinflation of the lungs , and increased  resistance to  airflow 
.which inurn Increases  the work ok breathing although  imbalances in 
ventilation Perfusion are seldom marked in as those in chronic  bronchitis, 
derangement sufficient  to   cause arterial hypoxemia  are common .  
CHRONIC OBSTRUCTIVE  
 Lung disease patients  are divided into  chronic 
bronchitisEmphysematous patients . Typically  they have  reduced  FEV1And 
reversibility less than 15 percent  while bronchial asthma patient have more     
15  percent   reversibility  .Then analysis of  symptoms and signs ofrpulmonale 
,pulmonary hypertension  was undertaken  
 
 Then  ECG , And ECHO CARDIOGRAM , X RAY CHEST  PA 
view, lateral view were taken   . And the ECG  is  looked for any evidence of 
pulmonary hypertension , right axis deviation , p wave morphology, RBBB, P 
wave amplitude  in 2, 3, avF  .  nd the  echocardiogram  was taken to look for 
any evidence of  pulmonary         hypertension    ,and tricuspid regurgitation.    
X-RAY chest PA view , and lateral  were  views  taken  to look for the 
presence Right heart hypertrophy , or small .pendulous heart of Emphysema       
 
LUNG FUNCTION 
 
GOLD has classified COPD as "a disease state characterized by airflow 
limitation that is not fully reversible. The airflow limitation is usually both 
progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles or gases" 18. This definition has also been adopted in 
the new ATS/ERS guidelines, with the important observation that COPD is 
both preventable and treatable 4. Impaired lung function is of central 
importance in the diagnosis of COPD. Airflow limitation is the slowing of 
expiratory airflow as measured by spirometry, with a persistently low forced 
expiratory volume in one second (FEV1) and a low FEV1/forced  vital capacity 
(FVC) ratio despite treatment. The current GOLD and ATS/ERS definition for 
airflow limitation is an FEV1/FVC ratio of <70% 4, 18. Although this "fixed" 
ratio is  easy to remember and simple, there is some concern that it may 
underestimate COPD in  younger populations, overestimate it in older ones, 
and misclassify other patients 19, 20. Declining lung function over time is an 
important component in understanding the natural history of COPD. The 
concept that different populations (i.e. susceptible smokers, nonsusceptible 
smokers, nonsmokers) have different trends in their lung function decline was 
developed by Peto et al. 21 and expanded by Burrows et al. 22. Interventions, 
such as smoking cessation, have been shown to alter this trend in populations, 
although individual patients may have a great deal of variability in their lung 
function decline over time 23.  
 
EPIDEMIOLOGY 
 
Prevalent COPD in the WORLD is influenced predominantly by 
smoking and age. Figure 1 shows age-specific GOLD categories of COPD 
stratified by smoking status, and shows that a high proportion of people aged 
65 yrs have evidence of COPD. Impaired lung function is an excellent 
predictor of both morbidity and mortality, including the development of lung 
cancer 25, functional impairments 26, elevated C-reactive protein levels 27, 
osteoporosis 28 and death 29. However, people with similar levels of impaired 
lung function may have markedly different outcomes. In an analysis of 
participants in the first National Health and Nutrition Examination Survey 
(NHANES) and follow-up, current and former smokers with GOLD stage 3 or 
4 COPD had a significantly increased mortality risk (compared with 
participants with no lung disease), whereas never-smokers with GOLD stage 3 
or 4 COPD did not have an increased mortality risk 29. The NHANES findings 
regarding lack of increase in mortality in nonsmokers with more severe disease 
has not been replicated in other studies. Celli et al. 30 demonstrated that an 
index that includes body mass, dyspnoea and the 6-min walk, in addition to 
lung function, is much better at predicting mortality than lung function alone.  
AIM   OF  STUDY 
 
 
 The  study   selects patients  with  cough , dyspnoea ,wheezOn 
the basis of pulmonary function test  and reversibility  and the presenting  signs 
and  symptoms  are analysed with ECG ,ECHO  TO FIND 
 
1. To know the cardiovascular  complications  of COPD  like 
pulmonary hypertension  
2. ECG    changes of   COPD  , 2 ,3 , AVF    P  WAVE  amplitude 
      Morphology , RBBB,  RVH , OR PHT   
3. Concurrent coronary artery disease patients   have increased 
incidence of right heart failure 
4. to confirm  with echocardiogram  the  presence of pulmonary 
hypertension and tricuspid regurgitation and right side failure and 
analyse the incidence of  right heart failure and pulmonary 
hypertension 
HISTORICAL OVERVIEW 
 
 Laennec divided  bronchitis into two   humid [ copious 
expectorationAnd dry[scarcely any expectorationRecognition  of chronic 
bronchitis  as  a potentially  grave illness rather  thanAs a trivial  but 
nondisabling disease had to await  the  LONDON FOG 1952This fog  brought  
about by bad weather and air pollutants carried with it a surge in morbidity and 
mortality  .Epidemiologists in the  united states ,netherlands , elsewhere  began 
to take serious stock of the   prevalence of chronic bronchitis and emphysema 
and  to  wonder why the diagnosis of   emphysema rarely appeared on the death 
certificates  in Great Britain  andwhy the diagnosis  of chronic bronchitis never 
appeared inthe  United states 
REVIEW OF LITERATURE 
 
 
DEFINITIONS  
Emphysema 
This entity  is  defined in anatomic terms -- abnormal  permanent Enlargement 
of the   gas –exchanging units of the  lungs[acini] in association With estruction  
of he alveolar walls and without obvious fibrosis The predominant physiologic 
consequence of  these  anatomic abnormalities. Is  a   decrease  in the  elastic  
recoil  of  the lungs – which in turn causes Outward  displacement of the  chest 
wall and flattening of the diaphragm Hyperinflation of the lungs , and increased  
resistance to  airflow .which inurn Increases  the work ok breathing  . although  
imbalances in ventilation  Perfusion  are seldom marked in as those in chronic  
bronchitis ,derangement sufficient  to   cause arterial hypoxemia  are common . 
CHRONIC   BRONCHITIS  
 
As  has been pointed out  chronic bronchitis  is not a  single 
clinicalEntity , and it is the airflow limitation that it produces that  leads 
toMorbidiy and mortaliy . this   limitation  has been  identified from a Decrease 
in FEV1  
 
CHRONIC OBSTRUCTIVE  PULMONARY DISEASE   
The  American Thoracic Society , defines  chronic obstructive 
pulmonaryDisease  [ COPD]  as a  disease state characterized by  the presence 
of airwayObstruction  due to chronic bronchitis or emphysema  ; the airflow 
obstruction is Generally  progressive ,may be accompanied by airway 
hypersensitivity  and may  be partially reversible   . Diagnostic of this non 
specific entity are  chronic productive cough, breathlessness on exertion, 
physiological evidence of  airflow Limitation[ reduced FEV1] ,and poor 
reversibility[ e.g , response to bronchodilator  
Asthma  
As  a rule clinicians believe that   they can identify most patients with 
atopic or extrinsic  asthma that begins in childhood and thosewith  intrinsic 
asthma of middle age .However ,uncertaintycreeps in when wheezing 
accompanies limitation to airflow   insome patients with  an acute exacerbation  
of bronchitis in thecourse of  COPD .The key elements in  the  differential 
diagnosisare  the reversibility in asthma to the obstruction to   airflow [ either 
by treatment or spontaneously] and hyper responsivenessof   the airways  .The  
diverse cause of asthma  are reflected in avariety of qualifiers  , such as  atopic 
occupational,cardiac, and cold induced. It is the  hyper responsiveness Of  
asthma that is responsible for the   widespread but reversible , narrowing of 
airways In  asthma ,  the larger bronchi are predominantly affected, goblet 
cellsUndergo  hyperplasia, bronchial glands hypertrophy, thebasement 
membrane  thickens , airway smooth muscle hypertrophies, and the luminal 
walls are invaded  by eosinophils .f and of shed  necrotic  bronchiolar 
epithelium. The inflammatory changes coupled with   submucosal edema , 
contribute  to the airway obstruction. 
 
Bronchiectasis 
Localizedbronchiectasis is ofen present in patients COPD  . As a rule , however 
bronchiectasis  is characerised by Dilatation of airways rather than by 
narrowing.it does not contribute to obstruction of air ways   in cysic 
fibrosisbronchiecatsis is  a common finding    .proximal airwaysdilated   distal 
airways are obstructed by mucoprulentexudates and  narrowed by obliterated 
airways. 
 
Bronchilolitis obliterans (and BOOP) 
 
 The lesions affected the terminal  branches of Branchial tree  where  
bronchi became devoid of their cartilage in their wall   caused by plugging of 
the terminal bronchioles ,fromwithin by organizing exudates , by constriction 
of bronchioles dueto inflammation and fibrosis, broncho alveolar process  
.causes are connective tissue disorders , toxic inhalants ,and cigarette 
smokingimmulogic disorders  ,infections in immunocompromised 
individualsafter allogenic bone transplantation as graft versus host reaction  
cytomegalo virus , adeno virus infection  ,the hall mark is presence of 
ranulation tissue  in he airways 
General 
appearance 
 
 
 
 
Age 
Onset 
 
Cyanosis 
 
Cough 
 
Sputum 
 
Uri 
 
Breath sounds 
 
Corpulmonale 
 
Radiograph 
 
 
 
 
 
course 
Mesomorphic 
overweight dusky 
Suffused conjuctiva 
warm extremities 
 
 
 
40--55 
cough 
 
marked  
 
more evident than 
dyspnea 
copious 
 
common 
 
moderately diminished 
 
common 
 
 
normal diaphragm   
cardiomegaly ,lungs 
normal with increased 
bronchovascular 
markings 
ambulatory but 
constantly on verge of 
right sided heart 
failure and coma 
 
Thin ,emaciated ,pursed lip 
breathing,anxious,prominent 
Use of accessory muscles ,normal or cool 
extremities 
 
 
 
50---75 
dyspnea 
 
slight o none 
 
less evident than  dyspnea  
 
scanty 
 
occasional 
 
markedly diminished 
 
terminally 
 
 
low ,flat diaphragm ,small pendulous 
heart,areas of increased radiolucency 
 
 
 
incapacitating breathlessness punctuated by 
life threatening bouts of upper respiratory 
infections,prolonged course culminating in 
right sided failure and coma 
 
  
 
FEV1 
 
FRC 
 
TLC 
 
RV 
 
LUNG COMPLIANCE 
 
Recoil pressure 
 
MVV 
 
Airway resistance  
 
 
Dco2 
 
Arterial po2 
 
Arterial hypercapnia 
 
 
Hematocrit  
 
Pulmonary artery 
pressure 
 
REDUCED 
 
Mildly increased  
 
Normal or slightly increased 
 
Normal or slightly increased 
 
Normal or low 
 
Normal or high 
 
Moderately decreased 
 
Increased 
 
 
Normal or low 
 
Marked reduction 
 
Chronic 
 
 
High  --70 
 
Increased 
 
REDUCED 
 
Markedly increased 
 
Considerably increased 
 
Considerably increased 
 
Normal or low 
 
Low 
 
Markedly decreased 
 
Normal or slightly 
increased 
 
Low 
 
Slight to moderate 
 
Only during acute 
respiratory infection 
 
Normal 55 
 
Normal or slightly 
increased 
Proposed  risk    factors   for  COPD 
 
Risk factor                                             comment 
Increasing age                                ventilatory impairment primarily reflects                                          
                                                        cumulative life time smoking    
 
gender                                             males more risk 
 
smoking                                           relation to cigarettes  smoking per day 
                                                         cumulative pack years 
 
environmental                                  more in urban 
 
occupation                                        more in coal  ,gold miners , farmers, cement 
                                                          cotton workers 
 
socioeconomic status                        common in low socio 
 
 
diet                                                    high fish may reduce risk 
 
genetic                                                alpha 1 anti trypsin deficiency 
 
 
birthweight                                           low birth weight lowFEV1 AND high COPD                       
                                                   later in life 
 
 
 
recurrent broncho pulmonary                  short term decline in lung function 
infections 
 
 
 
Allergy and airway                               increased eosinophils subgroup of smokers 
 hyper responsiveness  
 
Proteinase  inhibitors present  in  the Lung Parenchyma 
 
Proteinase inbitor 
 
Cell of origin proteinase inhibited 
 
Alpha 1 AT 
 
 
SLPI 
 
 
Elafin 
 
Aipha2  macroglobulin 
 
 
 
TIMP-1 
 
 
 
 
Cystatin C 
 
HEPATOCYTE 
 
 
Type 2 pneumocytes 
 
 
Large airway epithelial 
cells 
Hepatocytes,lung 
fibroblasts 
 
 
Macrophages, lung resident 
cells 
 
 
 
Bronchial epithelial cells 
 
Serine proteinase 
 
 
Serine proteinase 
 
Serine proteinase 
 
 
Serine proteinase 
 
 
MMPS 
 
 
 
 
cysteine proteinase 
 
INDICATIONS FOR HOSPITALISATION OF COPD PATIENTSAcute 
exacerbation [ increased dyspnea or sputum production]inadequate 
response to op management 
 
1. Inability to ambulate  
2. Inability to eat or sleep de to dyspnea 
3. Inadequate home care resources 
4. Serious co morbid conditions 
5. Prolonged progressive symptoms 
6. Altered mentation 
7. Worsening hypoxemia 
8. Worsening  hypercapnia 
9. New or worsening cor plmonale 
10. Surgical or diagnostic procedure 
Algorithm for the management of COPD 
Ipratropim [via MDI with spacer 
3, 6 pffs ,4 times a day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suboptimal 
response 
Add b2 agonist 2-6 puffs every 3-6 
hours as needed 
Suboptimal 
response 
Add long acting theophyline 
200 – 400 mg at bed time serum  
level 8—12 micro gram/ml 
Continued 
symptoms on 
maximal 
bronchodilators 
Trial of prednisone 
 
40 mg /day for 14 days 
<15   
improvement 
inFEV1discontue 
prednisone 
>15  
improvement 
inFEV1 low dose 
prednisone 
 BETA  ADRENERGICAGONISTS 
 
 
   Beta  adrenergic  agonists have been the mainstay   of  treatment of 
obstructive lung disease. These agents increase cyclic  adenosine 
monophosphate formation  which alters intracellular calcium homeostasisand  
modifies vascular tone .The drugs are best taken on as needed basis, hence they 
may be  used as primary therapy ,in patients who have dyspnea intermittently. 
They may be added to the  regular doses of ipratropium when patients have 
daily symptoms .Excessive use of beta agonist may result in tachyphylaxis via 
a down regulation of receptors. The side effects of beta agonists are  
tachycardia ,dysrhythmias,exacerbation of myocardial ischemia, and hypo or 
hypotension. Nervous system side effects include  tremor ,agitation, and 
insomnia. Fortunately tolerance develops to most of the side effects. 
Hypokalemia has been noted in patients receiving large dose sisoproterenol, 
isoetharine ,meaproterenol, terbutaline,albuterol,bitolterol pirbuteral 
,salmeterol are some of the beta adrenergic agonists  
 
 
 
 
 
 
 
 
 
 CORTICOSTEROIDS 
 
 Based  on  the    common  pathologic  finding  of  airway  
inflammation in COPD , use of corticosteroids  in  preventing  decline in   lung 
function has been  investigated.  In  one retrospective  study ,  daily oral doses 
of 10 mg of prednisone    produced  a    reduction   in the   rate of  decline  
ofFEV1  over 14 – 20 years  in patients with COPD  . More  recently  ,results.  
From  a ongoing study   indicate  addition of inhalational  steroid  to a 
bronchodilator  regimen may delay  the expected delay in FEV1   in patients 
with COPD  .In this study which includes  patients  with   reversible  airway 
obstruction  , long term inhaled  corticosteroids appear to be most effective  in 
subjects  with the greatest variability of air flow. Furthermore , although the 
decline in  FEV1 continued over time , airflow started from a new higher level   
hence the anti inflammatory effects of  corticosteroids  mayaffect  the  long 
term decline in  FEV, in COPD.  
 
 
 
 
 
 
 
 
 
Anti-cholinergic Agents 
 
Acetylcholine is a chemical released by nerves that attaches to receptors 
on the muscles surrounding the airway causing the muscles to contract and the 
airways to narrow. Anti-cholinergic drugs such as ipratropium bromide 
(Atrovent) dilate airways by blocking the receptors for acetylcholine on the 
muscles of the airways and preventing them from narrowing. Ipratropium 
bromide (Atrovent) usually is administered via a MDI. In patients with COPD, 
ipratropium has been shown to alleviate dyspnea, improve exercise tolerance 
and improve FEV1. Ipratropium has a slower onset of action but longer 
duration of action than the shorter-acting beta-2 agonists. Ipratropium usually 
is well tolerated with minimal side effects even when used in higher doses. 
Tiotropium (SPIRIVA) is a long acting and more powerful version of 
Ipratropium and has been shown to be more effective. In comparing 
ipratropium with beta-2 agonists in the treatment of patients with COPD, 
studies suggest that ipratropium may be more effective in dilating airways and 
improving symptoms with fewer side effects. Ipratropium is especially suitable 
for use by elderly patients who may have difficulty with fast heart rate and 
tremor from the beta-2 agonists. In patients who respond poorly to either beta-2 
agonists or ipratropium alone, a combination of the two drugs sometimes 
results in a better response than to either drug alone without additional side 
effects. 
 
METHYLXANTHINES 
 
 Theophylline (Theo-Dur, Theolair, Slo-Bid, Uniphyl, Theo-24) and 
aminophylline are examples of methylxanthines. Methylxanthines are 
administered orally or intravenously. Long acting theophylline preparations can 
be given orally once or twice a day. Theophylline, like a beta agonist, relaxes 
the muscles surrounding the airways but also prevents mast cells around the 
airways from releasing bronchoconstricting chemicals such as histamine. 
Theophylline also can act as a mild diuretic and increase urination. 
Theophylline also may increase the force of contraction of the heart and lower 
pressure in the pulmonary arteries. Thus, theophylline can help patients with 
COPD who have heart failure and pulmonary hypertension. Patients who have 
difficulty using inhaled bronchodilators but no difficulty taking oral 
medications find theophylline particularly useful. The disadvantage of 
methylxanthines is their side effects. Dosage and blood levels of theophylline 
or aminophylline have to be closely monitored. Excessively high levels in the 
blood can lead to nausea, vomiting, heart rhythm problems, and even seizures. 
In patients with heart failure or cirrhosis, dosages of methylxanthines are 
lowered to avoid high blood levels. Interactions with other medications, such as 
cimetidine (Tagamet), calcium channel blockers (Procardia), quinolones 
(Cipro), and allopurinol (Zyloprim) also can alter blood levels of 
methylxanthines. Interactions Aminoglutethimide, barbiturates, 
carbamazepine, ketoconazole, loop diuretics, charcoal, hydantoins, 
phenobarbital, phenytoin, rifampin, isoniazid, and sympathomimetics may 
decrease effects; effects may increase with allopurinol, beta-blockers, 
ciprofloxacin,corticosteroids, disulfiram, quinolones, thyroid hormones, 
ephedrine, carbamazepine, cimetidine, erythromycin, macrolides, propranolol, 
and interferon 
Future Directions in COPD 
 
As opposed to bronchial asthma, which has been well researched in the 
last 20 years, OPD has not been fully investigated. There is significant 
evidence that COPD is an inflammatory process just as is bronchial asthma, 
however, it seems that there are different patterns of lung inflammation in these 
patients. The mechanisms of baseline inflammation in COPD and inflammation 
during exacerbation of the disease need to be investigated and better 
understood. There is minimal or no information on the molecular mechanisms 
of inflammation in stable COPD patients. This latter issue becomes important 
particularly in the area of treatments. Currently, there are numerous clinical 
trials looking to intervene at the various inflammatory pathways. A newer class 
of medications that work to reduce this inflammation is being developed.They 
are referred to as PDE4 inhibitors. Drugs under investigation include 
rolipram,piclamilast, cilomilast, and Roflumilast. These inhibitors reduce the 
number and the activity of the different types of inflammatory cells and 
inflammatory substances seen in COPD  
 
FURTHER INPATIENT CARE: 
 
In cases in extremis, CPAP or BiPAP may be attempted prior to 
intubation. This can be started in the ED and continued for several hours in the 
hospital. Usual recommended settings are an inspiratory positive airway 
pressure (IPAP) of 10 cm H2O and an expiratory positive airway pressure 
(EPAP) of 2 cm H2O, with further adjustments based on the individual. This is 
contingent on the patient's ability to withstand the mask. This treatment is not a 
substitute for intubation; rather, it is a means of trying to avoid intubation. 
Heliox is an additional strategy that can be attempted prior to intubation. 
Whether Heliox or CPAP is used will depend on the individual patient and 
local hospital availability. Again, like several other therapies mentioned in this 
chapter, study results both for and against Heliox have been published. The 
current summation of that literature indicates that Heliox actually may decrease 
the work of breathing while the patient is breathing the mixture, but its effects 
are not long lasting once it is removed. The proper mixture of the gases and the 
ability to deliver enough oxygen to the patient also are issues. Inhaled nitric 
oxide has been suggested, but at this point does not seem to have a role in acute 
treatment. Lung volume reduction surgery has also been touted as effective, but 
most recent studies demonstrate varying levels of success. 
 
FURTHER OUTPATIENT CARE:  
 
Disposition from the ED depends on the clinical picture for each patient 
more than any single laboratory value or test. In general, the longer the 
exacerbation, the more airway edema and debris are present, making resolution 
in the ED increasingly more difficult. Patients who state that they "feel back to 
normal" and have no overt reason for admission can reasonably be discharged 
home with follow-up arrangements. The corollary to this is that patients who 
state they "do not feel comfortable," regardless of the numbers, are the best 
predictors of outcome and probably should be admitted. Data on risk factors for 
relapse and need for admission are limited at present. For patients who are sent 
home, nearly all should receive a short steroid burst and an increase in the 
frequency of inhaler therapy. Close follow-up should be arranged with the 
patient's regular care provider. Other therapies should be considered on a case-
by-case basis.  Patients with severe or unstable disease should be seen monthly. 
When their condition is stable, patients may be seen biannually. Check 
theophyl line level with each dose adjustment, then every 6-12 months. For 
patients on home oxygen, check ABGs yearly or with any change in condition. 
Monitor oxygen saturation more frequently than ABGs. 
COMPLICATIONS: 
Some complications that must be anticipated in COPD treatment include the 
following: Incidence of pneumothorax due to bleb formation is relatively high; 
consider pneumothorax in all patients with COPD who have increased 
shortness of breath. In patients who require long-term steroid use, the 
possibility of adrenal crisis is very real; at a minimum, patients with steroid-
dependent COPD should receive stress dosing in the event of an exacerbation 
or any other stressor. 
 
9 Infection (common) 
9 Cor pulmonale 
9 Secondary polycythemia 
9 Bullous lung disease 
9 Acute or chronic respiratory failure 
9 Pulmonary hypertension 
9 Malnutrition 
 
Prognosis:  
 
Patient's age and postbronchodilator FEV1 are the most important predictors of 
prognosis. Young age and FEV1 greater than 50% of predicted are associated 
with a good prognosis. Older patients and those with more severe lung disease 
do worse.Supplemental oxygen (when indicated) has been shown to increase 
survival rates. Smoking cessation improves prognosis. Cor pulmonale, 
hypercapnia, tachycardia, and malnutrition indicate a poor prognosis 
 
 
 
 
 
 
 
 
Hospital 
Admission 
 
inpatient
bed 
days 
 
general 
practice 
 
 
Chronic 
branchiis 
 
 
100 
 
 
1500 
 
 
4400 
 
Emphysema 
 
240 
 
3300 
 
2700 
 
Asthma 
 
410 
 
1800 
 
11900 
 
Total 750 6600 19000 
 
 
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lab Studies:  
 
Arterial blood gas 
Arterial blood gas (ABG) analysis provides the best clues as to acuteness 
and severity. 
In general, renal compensation occurs even in chronic CO2 retainers (ie, 
bronchitics); thus, pH usually is near normal. 
 
Generally, consider any pH below 7.3 a sign of acute respiratory 
compromise. 
Serum chemistry 
These patients tend to retain sodium. 
Diuretics, beta-adrenergic agonists, and theophylline act to lower 
potassium levels; thus, serum potassium should be monitored carefully. 
Beta-adrenergic agonists also increase renal excretion of serum calcium 
and magnesium, which may be important in the presence of hypokalemia. 
 
CBC - Polycythemia 
 
 
Imaging Studies:  
 
Chest x-ray 
Chronic bronchitis is associated with increased bronchovascular markings 
and cardiomegaly. 
 
Emphysema is associated with a small heart, hyperinflation, flat 
hemidiaphragms, and possible bullous changes. 
 
 
 
Other Tests:  
 
Pulse oximetry 
 
Pulse oximetry does not offer as much information as ABG. 
 
When combined with clinical observation, this test can be a powerful tool 
for instant  
 
feedback on the patient's status. 
 
Electrocardiogram 
 
The presence of underlying cardiac disease is highly likely. 
 
Establish that hypoxia is not resulting in ischemia. 
 
Establish that the underlying cause of respiratory difficulty is not cardiac 
in nature. 
 
 
Pulmonary function tests 
 
Decreased forced expiratory volume in 1 second (FEV1) with 
concomitant reduction in FEV1/forced vital capacity (FVC) ratio 
 
Poor/absent reversibility with bronchodilators 
 
FVC normal or reduced 
 
Normal or increased total lung capacity (TLC) 
 
Increased residual volume (RV) 
 
Normal or reduced diffusing capacity 
 
 
 
 
 
 
 
 
Pulmonary hypertension , cardiac function and fluid balance 
 
Pulmonary hypertension  develops  late in he course  of COPD   with the 
development of   hypoxemia [pa o2  < 8 kpa ,60 mm Hg] and usually 
hypercapnia. 
 
It is he most common cardiovascular complication of COPD, and is 
Associated with  the development of right ventricular failure 
 
Pulmonary circulation  
 
Changes occurs characteristically in he peripheral arteries in the 
pulmonary circulation of lungs.Among the earliest changes in the 
vasculature as  the airflow obstruction worsens is he thickening of the 
intima of the small pulmonary  arteries.Medial hypertrophy then develops 
in he muscular arteries.  Peripheral airway inflammation is associated 
with Pulmonary arterial thrombosis. 
 
There is increasing evidence to suggest  that  endothelial dysfunction 
Is an underlying factor. 
 
Thus the putative role of nitric oxide  in preventing  an excessive rise in 
pulmonary vascular tone as a result of hypoxemia may be lost.  
 
 
 
 
 
 
 
 
 
 
 
 
Factors  contributing to the development of 
pulmonary hypertension in  COPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Destruction of the pulmonary vascular bed 
 
Abnormal blood gas tensions 
 
Abnormal pulmonary mechanics 
 
Increased cardiac output 
 
Blood volume changes 
 
Increased blood velocity 
 
Endothelial abnormalities 
 
Haemo dynamics and blood gases in74 patients with  COPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               COPD                                                         NORMAL   
 
                                     Mean                 Range                                  Mean                                Range 
Pao2[mmHg]                   43                  23—67                                  91                                  75—105 
   
 
Paco2                              51                  33---68                                  38                                  32---- 43  
 
Cardiac output                3.8                 2.3—5.8                                3.6                                2.6----4.5 
 
Right arterial pressure      3                  0--- 21                                      5                                   2----- 9   
 
Mean pulmonary arterial  35               15---78                                   13                                   8----20 
 pressure 
 
Pulmonary vascular 
Resistance[dyens/s/cm2]   660           231—1377                             58                                 40-----200      
 
 
Right ventricular stroke work                      
Index                                 16              5---29                                     6                                      3------18 
 
Clinical assessment of pulmonary haemodynamics 
 
The presence of pulmonary hypertension produces loud p2,and a systolic 
parasternal heave indicates  right ventricular hypertrophy  
 
However  these clinical signs  are often difficult  to detect in patients  
with COPD  because of over inflation. 
 
Extra heart sounds like tricuspid regurgitation murmurs  best heard on 
 
Inspiration may be obscured by over inflation. 
 
The  jugular venous pulse is often difficult to detect because of large 
swings in Intra thoracic  pressure Peripheral edema is present in PHT  of 
COPD 
 
The presence of  pulmonary hypertension can be assumed on a plain chest 
Radiography if the right main pulmonary artery has a width of  more than  
16 mm 
 
Right ventricular hypertrophy is detected  in lateral view by 
encroachment of retrosternal space 
  
ECG CRITERIA right ventricular hypertrophy is detected by r wave 
height 
More than 5mm or r/s >50% 
 
Detectable tricuspid regurgitation by echo Doppler is probably the best 
Technique to measure pulmonary arterial pressure  non-invasively. 
Materials and  Methods 
 
 
 
Selection criteria* 
 
 
Step 1                          The patients  with  cough ,sputum  production 
dyspnea [wheeze] are  chosen and sputum AFB negative confirmed. 
 
 
Step 2   
                  Pulmonary function  test  was done  to pick up patients With 
reduced FEV< 80 %  were chosen 
 
step  3  
                          They   are nebulised  with  salbutamol bronchodilator 
And PFT  was done to select patients with < 15% reversibility  
 
 
Step 4  
                           They were clinically examined for  over inflation,ascites, 
edema, parasternal heave, JVP, loud P2 , tricuspid murmur 
 
 
 
 
 
 
 
 
 
 
 
Step 5  
               X ray chest PA view , lateral view taken to rule out the right 
pulmonary artery dilatation > 16mm [characteristic of pulmonary  arterial 
hypertension] lateral view to  rule out  retrosternal space 
obliteration[RVH] 
 
 
Step  6   
 
              ECG  was taken in patients to look for p wave Morphology , 
amplitude,2,+3 +,avF P  amplitude > 9mm,p axis, R wave > 5mm , 
r/s>50% ,RBBB ,  
 
 
Step  7    
 
             Echocardiogram  was done for the chosen patients chosen 
Looked for pulmonary arterial hypertension, and tricuspid regurgitation[ 
as it is the  non invasive  measure of pulmonary arterial pressure 
,surrogate , for measuring PAP] 
 
 
 
 
 
 
 
 
 
  
                     The patients were selected from the  coimbatore  medical 
  College hospital . 
 
They  are  interviewed for the symptoms like cough, dyspnea, 
wheeze. 
 
 
They were examined  to look for signs of pulmonary  hypertension, 
Corpulmonale. 
 
They  are subjected  to  pulmonary  function tests   to select 
patients with  
 
FEV1 < 80 , and  reversibility < 15  
 
 
Then  ECG , ECHO , taken for analysis.  
 
 
   
 
          
 
 
 
 
 
 
 
 
DATA ANALYSIS AND RESULTS 
 
 
 
OCCUPATION 
 
 
 
 
Farmers[rura] 
l 
urban people 
 
 
Cotton workers 
 
 
 
Textile workers 
 
 
Agricultural 
laborers[rural] 
 
 
 Workers in dye 
industry 
 
 
 
 
 
                      
    percentage 
 
  11             22% 
 
  20              40 % 
 
 
    3                 6% 
 
 
 
   7                 14 % 
 
 
 
   5                   10 % 
 
 
 
   4                    8 % 
 
 
 
 
                
 
 
 
 
 
RESULTS AND ANALYSIS COPD PATIENTS 
 
 
 
 
                    SEX WISE   ANALYSIS OF COPD  PATIENTS 
 
 
Sex  wise analysis of patients 
 
                                 percentage 
 
Male                 27/50               54 %  
 
 
Female             23/50                46% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age   wise   analysis 
 
Age group                Number         percentage                  
                                  of Copd    
 
 
40----50                     10                    20 %   
 
 
50----60                     22                   44 % 
 
 
60---70                      15                    30 %    
 
 
70—80                        3                    6 % 
   
                  
 
 
 
 
 
     
                                              
                      
 
                      
 
 
 
 
 
 
SYMPTOM    ANALYSIS OF COPD PATIENTS 
 
 
                      Percentage            
Cough       50                 100% 
 
Dyspnea    45                90% 
 
Wheeze      50              100% 
                          
 
 
 
HISTORY  ANALYSIS OF COPD PATIENTS 
 
 
Smoker       23/50 
More frequent 
Admissions     35/50 
                 
 
 
 
 
 
 
 
 
 
 
 
SIGN   ANALYSIS OF COPD  PATIENTS 
                         
 
           Signs                           num     percentage 
 
Jugular venous pulse              10       20% 
 
As cites                                     11        22% 
 
 
Edema                                     10        20% 
 
Parasternal heave                   10      20% 
 
Loud p2                                    11      22% 
        
 
 
PULMONARY  FUNCTION TEST ANALYSIS 
 
 
                             
PFT   FEV1  <    80 % 
50/50 
 
Reversibility   < 15 % 
50/50 
 
 
 
 
 
 
ECG  ANALYSIS OF COPD PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
ECG FINDING         NUM        percentage 
 
P pulmonale               17/50             34% 
 
Rt  axis                        29/50             58% 
 
R > 5mm                     5/50               10%   
 
2+3+avF p wave 
amplitude> 9mm        9/50            18% 
 
RBBB                       2/50                4% 
 
CAHD                       9/50                18% 
 
ECHO    ANALYSIS 
 
                     
 Complication 
PHT                   12/5O              
Tricuspid 
Regurgitation   11/50 
Percentage 
     24% 
 
     22% 
 
 
 
 
X  RAY ANALYSIS 
 
 
X RAY PA 
VIEW 
RVH                  13/50 
 
Lateral view     13/50 
  RVH 
                      
 
 
 
 
 
 
      
 
                                         
 
 
 
 
                           
 
 
 
 
 
DISEASE   ANALYSIS 
 
 
Pulmonary               NO        percentage 
Hypertension            12          24% 
 
Corpulmonale           9           18% 
 
Emphysema             11            22% 
 
COPD Bronchitis     18           36 % 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                          
DISCUSSION 
 
 
                  From  the    above data and analysis , It is clear male  patients 
with Smoking history is more prone for  COPD , in particular 
Emphysema.  Out of the  fifty patients , 27 patients were males  . among 
them 23  Patients were smokers  .out of these 23 , 13  males presented 
with ,cough , Dyspnea.,   Wheeze. 
 
 
 
                Radiologically all the  13  patients showed small ,  pendulous                     
heart , with.  Flattened diaphragm   and increased radiolucency   with 
widened      intercostals spaces [ hyperinflation] 
 
 
 
                 Among  the 50 ,  12    were echocardiographically  had  
pulmonary  hypertension 11 had tricuspid regurgitation [ which is a 
noninvasive measure of   pulmonary arterial pressure, which we can not 
afford to measure via catheter. 
 
 
 
 
 
 
 
                          
 
 
            Among the  50 patients   ECG     17 patients had  p pulmonale,29        
Patients had right axis, deviation  5 had **r ** wave height more than 5 
mm [ indicating they had severe  Right ventricular hypertrophy  or  
pulmonary hypertension. 
 
 
 
 
                          9 had  2+3+avF > 9 mm  of  p  wave amplitude this   is 
specifically taken  Into   consideration as  this [ 2+3+avF  > 9mm ] is an 
indication for Long term  oxygen  therapy in  copd patients as per 
the American Thoracic  Society . 
 
 
 
 
                         Also  the   ECGs were looked for  any  ischemic 
heart disease 9 Out  of 50 had  CAHD  . as this increases the 
incidence of corpulmonale [ smoking is an risk facor for both 
COPD [Emphysema, Bronchitis]   and  CAHD. 
 
 
 
                 
                                  
 
 
 
 
                    
Industrialization and impact   
 
 
Out of the fifty  patients  fourteen patients  were working in   
various  industries in  coimbatore . seven were working in  textile   
industry ,  while  four   were working in  dye industry  , three  were 
working in  cotton mills  .out  seven  workers  in textile 5 patients  
were smokers ,2 females are non smokers . four  textile workers  
had bronchitis  , 2 were   emphysematous 1 had mild copd . 
generally  the incidence of  emphysema  was more common  in 
smokers 13 /23 in the group of 50 patients . in  smokers working in 
textile mills it was the bronchitis  that was more  common.  while 
smoking commonly produce centri acinar emphysema , in textile 
workers the fine fabric related  chemical particles  increase the 
incidence of  bronchitis in these  patients. In  dye related workers 
ou of the four 2 were emphysematous , and 2  had mild degree of 
copd  in  the 3  cotton workers  2 had bronchitis , 1 had  mild copd  
 
 
 
 
 
 
 
 
 
 
 
Urbanization  and impact 
 
out of the fifty   copd patients ,20 were from urban areas .among 
the twenty  9 were urban females without smoking history , but 
they had copd . seven had  bronchitis, one had mild  copd ,one 
had  emphysema .this indicates the increased level pollution in   
urban  areas .11 males were  copd patients .all the 11 were 
smokers  and nine out the11 were emphysematous ,2 were 
bronchitis  patients . While just  16  out of  50 were from rural 
areas , the major air pollutants were released from automobiles 
like  carbon monoxide, carbon dioxide , sulpurdioxide  ,lead.  So 
urbanization  had its toll , by increasing  the level of pollutants.   In  
the air and increasing the number of copd  patients  even though  
coimbatore has green trees all around I had  high   level   of copd 
patients  .so we want strict pollution control acts which should be 
implemented strictly .  
                           
 
                          
  
 
 
 
 
 
 
 
 From the above   data   we can infer  that the rapid pace of 
Urbanization, pollution of air , textile industry , dye industry ,cotton 
industry  , farming activities , smoking  are major triggers  for copd  
more over the complications of copd like pulmonary hypertension  
corpulmonale   were better found by ecg and echocardiogram.   
The  use of ecg  was in detecting  the patients who need o2 
Therapy  [ if  the  combined 2+3+avF  P wave amplitude more than 
9 mm ]  . the evidence of  pulmonary hypertension  right  
Ventricular hypertrophy  ,detected well ,. Normally it is difficult to  
Estimate  pulmonary arterial pressure   invasively via catheter but  
Easy  to measure it indirectly if we measure it by detecting  
Tricuspid regurgitation  nonivasively by echocardiogram .11   
patients  had tricuspid regurgiation.                      
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiovascular complications 
 
 
           Out of  the 50 COPD  patients  , 24 %   developed  pulmonary  
hypertension,  22   % developed    tricuspid  regurgitation .the chronic  
hypoxia of COPD  is responsible for the  development  of pulmonary 
hypertension.the  tricuspid  regurgitation   is the  best  possible  non 
invasive way of measuring  pulmonary artery  pressure  
 
34 % patients had p  pulmonale , 18  % patients had the total 
p wave amplitude in  2, 3 , avF  more than  9 mm , this is important  
because  this one  of  the  indication  for  life long  oxygen  therapy. 
 
          18% patients   had concomitant  CAHD ,this observation is 
important, becase systemic inflammation  plays enhanced role in 
atherosclerosis, diabetes.  TNF  alpha  is increased in  COPD, 
patients  
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
Pulmonary    hypertension  was the  major cardiovascular 
complication  of COPD ,  the chronic hypoxia of  COPD is   
responsible for the  development of pulmonary  hypertension  .24 
percent of the total cases had pulmonary hypertension. The need 
for  life long oxygen therapy  was reemphasized  in this study by 
establishing  that  nine patients  had  p  wave amplitude 
summation in 2 , 3 ,  av F  of more than    9 mm .   
 
 
The  study also   established  that the  best  non invasive 
way  to detect   raised  pulmonary   arterial    pressure  was  
detecting  tricuspid    regurgitation   by echocardiogram.   
 
   
Males  Predominantly  had  Emphysema   female  had 
predominantly  Chronic Bronchitis  with  corpulmonale  
 
9 /50 had  2+3+avF *P* wave amplitude > 9m  as this the 
one of the indication for **Long Term Oxygen Therapy as per The 
American Thoracic Society**. 
 
 
            
              
 Urbanization , pollution of air , textile industry , dye industry 
,cotton industry  , farming activities , smoking  are major triggers  
for copd  more over the complications of copd like pulmonary 
hypertension corpulmonale   were better found by ecg and 
echocardiogram. 
  
The  use of ecg  was in detecting  the patients who need o2 
Therapy  [ if  the  combined 2+3+avF  P wave amplitude more than 
9 mm ]  . the evidence of  pulmonary hypertension  right 
Ventricular  hypertrophy were, detected well,. Normally it is difficult 
to  Estimate  pulmonary arterial pressure   invasively via catheter 
but Easy  to measure it indirectly if we measure it by detecting 
Tricuspid regurgitation  nonivasively by echocardiogram. 18% 
patients   had concomitant  CAHD ,this observation is                  
important, because systemic inflammation  plays enhanced role in        
atherosclerosis , diabetes  .[TNF  alpha  is increased in  COPD, 
patients ] 
 
 
 
 
 
 
 
 
 Finally  the study by analyzing  COPD  patients with  clinical 
arameters ,  ECG ,  ECHOCARDIOGRAM,   concluded that 
pulmonary hypertension  was the  most common cardiovascular 
complication  leading to cor pulmonale, and  emphysema was 
more common in smokers , bronchitis was more common in 
females , the  prevalence of COPD  was more in urban  areas  due 
o pollution of air by automobiles. The textile based industries  were 
mainly responsible for the increased prevalence of COPD  .                   
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ABBREVIATIONS IN  MASTER CHART 
 
 
Paraste------------- parasternal heave 
Freqadi-------------- frequency of admission 
Reversi--------------- reversibility 
P pulmonale---------p pulmonale 
Rbbb-------------------right bundle branch block 
CAHD----------------- coronary artery disease  
PHT---------------------pulmonary hypertension 
TR-----------------------tricuspid regurgitation 
 p-------------------------present, 
A-------------------------- absent      
R----------------------------right axis deviation 
RVH---------------------- right ventricular hypertrophy 
Small hear-------------- small heart 
Ne------------------------- sputum AFB negative     
N---------------------------- normal axis 
Ag -------------------------- agricultural worker 
urb -------------------------- urban 
Fa ----------------------------farmer 
Co ---------------------------- cotton 
Tex ----------------------------Textile worker 
Dye---------------------------- dye industry worker 
Oc------------------------------ occupation 
     
 
 
                        
 
 
 S.No IP no Age Sex 
co
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ci
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pa
ra
st
he
 
lo
ud
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fr
eq
ua
dl
  
FE
V
1<
80
 
re
ve
rs
i<
15
 
p 
pu
lm
on
a 
1 446022 56 male p A P A A A A A   P P P P A 
2 467211 42 female P P P P P P P P A P P P P 
3 468123 57 male P P P A A A A A   P P P P A 
4 487199 63 female p p p p p A A A   A A P P P 
5 486612 57 female P P P A A A A A   A P P P P 
6 486954 60 MALE P P P A A A A A   P P P P A 
7 495163 55 female p p p A A A A A   A A P P A 
8 494251 40 female p A P A A A A A   A A P P A 
9 498190 51 MALE P P P P P P P P P P P P P 
10 504253 65 male P P P A A A A A   P P P P A 
11 467239 60 female P P P A A A A A   A P P P A 
12 516345 63 male P P P A A A A A   PP P P P A 
13 485273 56 female P P P A P P P P A P P P P 
14 494590 61 female p p p A A A A AA A A P P A 
15 495662 71 female P P P P P P P P P P P P P 
16 506011 63 male P P P A A A A A A P P P A 
17 506155 52 male p p P A A A A A P P P P A 
18 515342 61 female P P P P P P P P A P P P P 
19 512234 65 male P P P A A A A A P P P P A 
20 503341 43 female p p p A A A A A A A P P A 
21 512345 51 male P P P A A A A A P P P P A 
22 523445 60 male P P P P P P P P P P P P P 
23 523612 45 female P P P A A A A A A A P P A 
24 534323 56 female P P P A A A A A A P P P A 
25 533223 70 male P P P A A A A A P P P P A 
26 543122 56 male P A P A A A A P P P P A A 
27 542231 44 female P A P A A A A A A A P P A 
28 523423 67 MALE P P P A A A A A PPP P P A N 
29 543121 41 female p p p A A A A A A A P P P 
30 554554 60 male P P P A A A A A A A P P P 
31 556231 54 male P P P A A A A A P P P P A 
32 551133 46 female P A P A A A A A A A P P A 
33 551245 57 male P P P A A A A A PP P P P A 
34 555672 75 female p p p p p p p p A P P P P 
35 562136 63 male p p p p p p p P A P P P P 
36 567341 69 male P P P A A A A A P P P P A 
37 564672 49 female P P P A A A A A A A P P P 
38 564533 46 male P P P A A A A A A A P P P 
39 579447 61 male P P P A A A A A PP P P P A 
40 576764 59 female p P P A A A A A A P P P A 
41 576642 65 male p P P A A A A A P P P P A 
42 587554 52 female P P P A A A A A A P P P P 
43 586121 45 male P P P A A A A A P A P P A 
44 596214 54 female P P P A A A A A A P P P A 
45 595342 65 male P P P A A A A A P P P P A 
46 602342 60 male p p P A A A A A A A P P A 
47 607234 72 female p p p P P P P P A P P P P 
48 607245 59 male P P P A A A A A P A P P A 
49 607754 64 female P P P P P P P P A P P P P 
50 608765 65 male P P P A A A A A PP P P P A 
 
 
